Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Abbott Laboratories, profitability ratios (quarterly data)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Abbott Laboratories gross profit margin ratio improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Abbott Laboratories operating profit margin ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Abbott Laboratories net profit margin ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Abbott Laboratories ROE improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Abbott Laboratories ROA improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Gross Profit Margin
Abbott Laboratories, gross profit margin calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Gross profit | 5,567) | 5,467) | 5,303) | 5,029) | 5,204) | 5,042) | 4,997) | 4,925) | 5,002) | 5,283) | 5,817) | 6,396) | 6,188) | 5,985) | 4,772) | 5,546) | 5,700) | 4,377) | 3,512) | 3,884) | ||||||
| Net sales | 10,974) | 10,635) | 10,377) | 9,964) | 10,241) | 10,143) | 9,978) | 9,747) | 10,091) | 10,410) | 11,257) | 11,895) | 11,468) | 10,928) | 10,223) | 10,456) | 10,701) | 8,853) | 7,328) | 7,726) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | 50.93% | 50.96% | 50.53% | 50.27% | 50.28% | 49.97% | 50.23% | 50.66% | 51.54% | 52.60% | 53.54% | 52.44% | 52.21% | 52.01% | 50.69% | 51.25% | 50.49% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Cigna Group | 10.15% | 10.83% | 11.41% | 11.90% | 12.37% | 12.28% | 12.19% | 12.39% | 12.44% | 12.39% | 12.40% | 12.30% | 12.41% | 12.77% | 13.13% | 14.04% | 14.43% | — | — | — | ||||||
| CVS Health Corp. | 13.29% | 13.81% | 14.37% | 14.55% | 14.94% | 15.34% | 15.69% | 16.16% | 16.62% | 16.94% | 17.12% | 17.35% | 17.48% | 17.35% | 17.43% | 17.99% | 18.01% | — | — | — | ||||||
| Elevance Health Inc. | 15.92% | 16.62% | 17.16% | 16.92% | 16.79% | 16.86% | 16.89% | 16.90% | 16.79% | 16.85% | 16.79% | 16.89% | 17.09% | 17.30% | 17.57% | 19.38% | 19.71% | — | — | — | ||||||
| Intuitive Surgical Inc. | 67.46% | 66.98% | 66.86% | 66.43% | 66.39% | 66.61% | 66.74% | 66.86% | 67.44% | 67.77% | 68.16% | 68.84% | 69.32% | 69.12% | 68.69% | 66.48% | 65.65% | — | — | — | ||||||
| Medtronic PLC | 65.34% | 65.50% | 65.40% | 65.68% | 65.67% | 66.43% | 67.21% | 67.61% | 67.98% | 67.89% | 67.39% | 66.53% | 65.19% | 63.85% | 64.57% | 65.76% | 67.41% | 68.96% | 69.22% | 69.62% | ||||||
| UnitedHealth Group Inc. | 21.31% | 21.91% | 22.63% | 23.18% | 23.64% | 24.16% | 24.08% | 24.20% | 24.09% | 23.74% | 23.51% | 23.31% | 23.60% | 23.75% | 23.80% | 25.79% | 25.62% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Gross profit margin = 100
× (Gross profitQ4 2024
+ Gross profitQ3 2024
+ Gross profitQ2 2024
+ Gross profitQ1 2024)
÷ (Net salesQ4 2024
+ Net salesQ3 2024
+ Net salesQ2 2024
+ Net salesQ1 2024)
= 100 × (5,567 + 5,467 + 5,303 + 5,029)
÷ (10,974 + 10,635 + 10,377 + 9,964)
= 50.93%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Abbott Laboratories gross profit margin ratio improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024. |
Operating Profit Margin
Abbott Laboratories, operating profit margin calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Operating earnings | 1,911) | 1,859) | 1,669) | 1,386) | 1,780) | 1,647) | 1,542) | 1,509) | 1,304) | 1,770) | 2,376) | 2,912) | 2,378) | 2,546) | 1,392) | 2,109) | 2,432) | 1,495) | 672) | 758) | ||||||
| Net sales | 10,974) | 10,635) | 10,377) | 9,964) | 10,241) | 10,143) | 9,978) | 9,747) | 10,091) | 10,410) | 11,257) | 11,895) | 11,468) | 10,928) | 10,223) | 10,456) | 10,701) | 8,853) | 7,328) | 7,726) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | 16.27% | 16.24% | 15.92% | 15.76% | 16.15% | 15.02% | 15.23% | 16.77% | 19.16% | 20.95% | 22.42% | 20.73% | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Cigna Group | 3.83% | 4.02% | 4.14% | 4.29% | 4.40% | 4.34% | 4.38% | 4.54% | 4.69% | 4.59% | 4.71% | 4.64% | 4.60% | 4.59% | 4.57% | 4.98% | 5.12% | — | — | — | ||||||
| CVS Health Corp. | 2.30% | 2.59% | 3.42% | 3.49% | 3.85% | 4.04% | 1.88% | 2.33% | 2.41% | 2.02% | 4.35% | 4.39% | 4.54% | 4.75% | 4.93% | 5.19% | 5.19% | — | — | — | ||||||
| Elevance Health Inc. | 4.16% | 4.55% | 4.76% | 4.64% | 4.47% | 4.58% | 4.96% | 4.99% | 4.94% | 5.01% | 5.07% | 5.10% | 5.15% | 4.91% | 3.68% | 4.83% | 4.97% | — | — | — | ||||||
| Intuitive Surgical Inc. | 28.12% | 26.24% | 25.79% | 25.26% | 24.80% | 24.66% | 24.34% | 24.21% | 25.35% | 27.05% | 28.48% | 30.69% | 31.89% | 32.55% | 31.27% | 26.01% | 24.09% | — | — | — | ||||||
| Medtronic PLC | 15.89% | 17.50% | 17.41% | 17.83% | 17.56% | 18.17% | 19.02% | 19.37% | 18.15% | 17.89% | 16.68% | 14.78% | 14.89% | 11.44% | 12.77% | 14.25% | 16.57% | 20.67% | 20.47% | 21.25% | ||||||
| UnitedHealth Group Inc. | 8.17% | 8.28% | 8.40% | 8.58% | 8.80% | 8.86% | 8.83% | 8.87% | 8.83% | 8.65% | 8.32% | 8.19% | 8.40% | 7.91% | 7.73% | 9.24% | 8.76% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Operating profit margin = 100
× (Operating earningsQ4 2024
+ Operating earningsQ3 2024
+ Operating earningsQ2 2024
+ Operating earningsQ1 2024)
÷ (Net salesQ4 2024
+ Net salesQ3 2024
+ Net salesQ2 2024
+ Net salesQ1 2024)
= 100 × (1,911 + 1,859 + 1,669 + 1,386)
÷ (10,974 + 10,635 + 10,377 + 9,964)
= 16.27%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Abbott Laboratories operating profit margin ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Net Profit Margin
Abbott Laboratories, net profit margin calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net earnings | 9,229) | 1,646) | 1,302) | 1,225) | 1,594) | 1,436) | 1,375) | 1,318) | 1,033) | 1,435) | 2,018) | 2,447) | 1,989) | 2,100) | 1,189) | 1,793) | 2,162) | 1,232) | 537) | 564) | ||||||
| Net sales | 10,974) | 10,635) | 10,377) | 9,964) | 10,241) | 10,143) | 9,978) | 9,747) | 10,091) | 10,410) | 11,257) | 11,895) | 11,468) | 10,928) | 10,223) | 10,456) | 10,701) | 8,853) | 7,328) | 7,726) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | 31.95% | 13.99% | 13.65% | 13.96% | 14.27% | 12.92% | 12.83% | 13.98% | 15.88% | 17.52% | 18.78% | 17.35% | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Cigna Group | 1.40% | 1.31% | 1.71% | 1.77% | 2.66% | 2.81% | 3.59% | 3.71% | 3.72% | 3.69% | 3.08% | 3.07% | 3.11% | 4.97% | 4.93% | 5.22% | 5.31% | — | — | — | ||||||
| CVS Health Corp. | 1.24% | 1.37% | 1.99% | 2.04% | 2.34% | 2.48% | 0.86% | 1.20% | 1.29% | 1.00% | 2.66% | 2.68% | 2.72% | 2.67% | 2.60% | 2.74% | 2.68% | — | — | — | ||||||
| Elevance Health Inc. | 3.41% | 3.72% | 3.93% | 3.66% | 3.52% | 3.63% | 3.89% | 3.89% | 3.87% | 4.09% | 4.13% | 4.37% | 4.46% | 4.17% | 3.32% | 3.82% | 3.78% | — | — | — | ||||||
| Intuitive Surgical Inc. | 27.81% | 28.51% | 27.65% | 27.16% | 25.24% | 22.14% | 21.38% | 20.40% | 21.25% | 22.52% | 24.05% | 27.84% | 29.85% | 30.78% | 31.43% | 25.78% | 24.33% | — | — | — | ||||||
| Medtronic PLC | 11.36% | 13.00% | 12.84% | 11.47% | 12.03% | 13.20% | 14.03% | 16.75% | 15.90% | 15.46% | 14.79% | 12.29% | 11.97% | 10.36% | 12.69% | 15.80% | 16.56% | 17.11% | 15.11% | 14.41% | ||||||
| UnitedHealth Group Inc. | 3.65% | 3.68% | 3.70% | 4.09% | 6.09% | 6.09% | 6.11% | 6.21% | 6.25% | 6.21% | 5.99% | 5.91% | 6.06% | 5.56% | 5.37% | 6.46% | 6.03% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Net profit margin = 100
× (Net earningsQ4 2024
+ Net earningsQ3 2024
+ Net earningsQ2 2024
+ Net earningsQ1 2024)
÷ (Net salesQ4 2024
+ Net salesQ3 2024
+ Net salesQ2 2024
+ Net salesQ1 2024)
= 100 × (9,229 + 1,646 + 1,302 + 1,225)
÷ (10,974 + 10,635 + 10,377 + 9,964)
= 31.95%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Abbott Laboratories net profit margin ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Return on Equity (ROE)
Abbott Laboratories, ROE calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net earnings | 9,229) | 1,646) | 1,302) | 1,225) | 1,594) | 1,436) | 1,375) | 1,318) | 1,033) | 1,435) | 2,018) | 2,447) | 1,989) | 2,100) | 1,189) | 1,793) | 2,162) | 1,232) | 537) | 564) | ||||||
| Total Abbott shareholders’ investment | 47,664) | 39,796) | 39,318) | 38,810) | 38,603) | 37,481) | 37,174) | 37,010) | 36,686) | 35,675) | 36,490) | 35,399) | 35,802) | 34,422) | 33,800) | 33,562) | 32,784) | 31,386) | 30,578) | 30,218) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | 28.12% | 14.49% | 14.13% | 14.51% | 14.83% | 13.77% | 13.88% | 15.68% | 18.90% | 22.11% | 23.44% | 21.82% | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| Cigna Group | 8.37% | 7.22% | 8.97% | 8.79% | 11.17% | 11.61% | 14.64% | 15.17% | 14.86% | 14.69% | 11.94% | 11.69% | 11.39% | 17.68% | 16.73% | 17.52% | 16.81% | — | — | — | ||||||
| CVS Health Corp. | 6.11% | 6.69% | 9.60% | 9.90% | 10.91% | 11.57% | 4.02% | 5.57% | 5.84% | 4.46% | 10.86% | 10.83% | 10.54% | 10.20% | 9.83% | 10.44% | 10.35% | — | — | — | ||||||
| Elevance Health Inc. | 14.47% | 14.66% | 15.86% | 15.38% | 15.23% | 15.82% | 16.78% | 16.62% | 16.59% | 17.26% | 17.04% | 17.36% | 16.93% | 15.44% | 12.10% | 13.92% | 13.77% | — | — | — | ||||||
| Intuitive Surgical Inc. | 14.13% | 14.39% | 14.23% | 14.24% | 13.51% | 12.10% | 12.00% | 11.70% | 11.98% | 11.97% | 11.93% | 13.58% | 14.32% | 14.80% | 14.97% | 11.56% | 10.90% | — | — | — | ||||||
| Medtronic PLC | 7.32% | 8.11% | 7.97% | 7.07% | 7.30% | 7.90% | 8.33% | 9.88% | 9.59% | 9.35% | 9.05% | 7.54% | 7.01% | 5.70% | 7.05% | 8.77% | 9.44% | 10.26% | 9.23% | 8.78% | ||||||
| UnitedHealth Group Inc. | 15.55% | 15.14% | 15.78% | 17.72% | 25.22% | 25.67% | 25.63% | 25.46% | 25.87% | 26.03% | 25.07% | 23.98% | 24.09% | 21.95% | 21.03% | 25.42% | 23.52% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
ROE = 100
× (Net earningsQ4 2024
+ Net earningsQ3 2024
+ Net earningsQ2 2024
+ Net earningsQ1 2024)
÷ Total Abbott shareholders’ investment
= 100 × (9,229 + 1,646 + 1,302 + 1,225)
÷ 47,664 = 28.12%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Abbott Laboratories ROE improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Return on Assets (ROA)
Abbott Laboratories, ROA calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net earnings | 9,229) | 1,646) | 1,302) | 1,225) | 1,594) | 1,436) | 1,375) | 1,318) | 1,033) | 1,435) | 2,018) | 2,447) | 1,989) | 2,100) | 1,189) | 1,793) | 2,162) | 1,232) | 537) | 564) | ||||||
| Total assets | 81,414) | 74,356) | 73,017) | 72,467) | 73,214) | 72,090) | 73,354) | 73,794) | 74,438) | 72,801) | 74,202) | 74,007) | 75,196) | 73,795) | 73,269) | 72,785) | 72,548) | 69,043) | 68,776) | 66,777) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | 16.46% | 7.76% | 7.61% | 7.77% | 7.82% | 7.16% | 7.04% | 7.87% | 9.31% | 10.84% | 11.53% | 10.44% | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| Cigna Group | 2.20% | 1.93% | 2.39% | 2.36% | 3.38% | 3.54% | 4.43% | 4.56% | 4.63% | 4.59% | 3.59% | 3.53% | 3.46% | 5.44% | 5.29% | 5.55% | 5.44% | — | — | — | ||||||
| CVS Health Corp. | 1.82% | 1.99% | 2.85% | 2.93% | 3.34% | 3.42% | 1.17% | 1.66% | 1.82% | 1.36% | 3.55% | 3.43% | 3.39% | 3.23% | 3.12% | 3.22% | 3.11% | — | — | — | ||||||
| Elevance Health Inc. | 5.12% | 5.51% | 5.92% | 5.58% | 5.50% | 5.50% | 5.87% | 5.69% | 5.86% | 6.03% | 6.05% | 6.21% | 6.26% | 5.63% | 4.40% | 4.93% | 5.28% | — | — | — | ||||||
| Intuitive Surgical Inc. | 12.39% | 12.64% | 12.57% | 12.56% | 11.64% | 10.31% | 10.25% | 10.05% | 10.19% | 10.39% | 10.47% | 12.02% | 12.58% | 13.06% | 13.20% | 10.17% | 9.50% | — | — | — | ||||||
| Medtronic PLC | 4.09% | 4.63% | 4.55% | 3.99% | 4.13% | 4.32% | 4.63% | 5.79% | 5.54% | 5.35% | 5.13% | 4.23% | 3.87% | 2.97% | 3.69% | 4.70% | 5.28% | 5.73% | 5.13% | 4.84% | ||||||
| UnitedHealth Group Inc. | 4.83% | 4.78% | 4.93% | 5.40% | 8.18% | 7.69% | 7.53% | 7.30% | 8.19% | 7.99% | 7.93% | 7.89% | 8.15% | 7.24% | 6.90% | 8.23% | 7.81% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
ROA = 100
× (Net earningsQ4 2024
+ Net earningsQ3 2024
+ Net earningsQ2 2024
+ Net earningsQ1 2024)
÷ Total assets
= 100 × (9,229 + 1,646 + 1,302 + 1,225)
÷ 81,414 = 16.46%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Abbott Laboratories ROA improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |